nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—bone cancer—skin cancer	0.2	0.41	CtDrD
Doxorubicin—peripheral nervous system neoplasm—skin cancer	0.147	0.3	CtDrD
Doxorubicin—sarcoma—skin cancer	0.141	0.289	CtDrD
Doxorubicin—ABCC6—Dactinomycin—skin cancer	0.0646	0.209	CbGbCtD
Doxorubicin—ABCC1—Vemurafenib—skin cancer	0.0287	0.0927	CbGbCtD
Doxorubicin—ABCC10—Docetaxel—skin cancer	0.0255	0.0824	CbGbCtD
Doxorubicin—ABCG2—Vismodegib—skin cancer	0.0243	0.0785	CbGbCtD
Doxorubicin—ABCC3—Fluorouracil—skin cancer	0.021	0.0678	CbGbCtD
Doxorubicin—ABCG2—Vemurafenib—skin cancer	0.0192	0.062	CbGbCtD
Doxorubicin—ABCC1—Dactinomycin—skin cancer	0.0191	0.0616	CbGbCtD
Doxorubicin—CYP1B1—Docetaxel—skin cancer	0.0139	0.0448	CbGbCtD
Doxorubicin—ABCG2—Dactinomycin—skin cancer	0.0128	0.0412	CbGbCtD
Doxorubicin—ABCC1—Docetaxel—skin cancer	0.00984	0.0318	CbGbCtD
Doxorubicin—ABCB1—Vismodegib—skin cancer	0.00876	0.0283	CbGbCtD
Doxorubicin—ABCG2—Fluorouracil—skin cancer	0.00863	0.0279	CbGbCtD
Doxorubicin—CYP3A4—Imiquimod—skin cancer	0.00757	0.0245	CbGbCtD
Doxorubicin—CYP3A4—Temozolomide—skin cancer	0.00757	0.0245	CbGbCtD
Doxorubicin—ABCC2—Docetaxel—skin cancer	0.00729	0.0235	CbGbCtD
Doxorubicin—ABCG2—Docetaxel—skin cancer	0.00659	0.0213	CbGbCtD
Doxorubicin—CYP2D6—Vemurafenib—skin cancer	0.00652	0.0211	CbGbCtD
Doxorubicin—CYP3A4—Vismodegib—skin cancer	0.00525	0.0169	CbGbCtD
Doxorubicin—ABCB1—Dactinomycin—skin cancer	0.0046	0.0149	CbGbCtD
Doxorubicin—CYP3A4—Vemurafenib—skin cancer	0.00415	0.0134	CbGbCtD
Doxorubicin—ABCC6—dermis—skin cancer	0.0027	0.0483	CbGeAlD
Doxorubicin—ABCB1—Docetaxel—skin cancer	0.00238	0.00767	CbGbCtD
Doxorubicin—NOS1—penis—skin cancer	0.00232	0.0415	CbGeAlD
Doxorubicin—NOS3—penis—skin cancer	0.00176	0.0315	CbGeAlD
Doxorubicin—CBR3—hair follicle—skin cancer	0.00152	0.0272	CbGeAlD
Doxorubicin—CYP3A4—Docetaxel—skin cancer	0.00142	0.0046	CbGbCtD
Doxorubicin—NOS3—hindlimb—skin cancer	0.00133	0.0238	CbGeAlD
Doxorubicin—AKR1A1—hair follicle—skin cancer	0.00118	0.021	CbGeAlD
Doxorubicin—NOS3—appendage—skin cancer	0.00114	0.0204	CbGeAlD
Doxorubicin—NOS1—nerve—skin cancer	0.00106	0.019	CbGeAlD
Doxorubicin—CBR3—nipple—skin cancer	0.00103	0.0185	CbGeAlD
Doxorubicin—AURKA—Sorafenib—Vismodegib—skin cancer	0.000952	0.605	CbGdCrCtD
Doxorubicin—NOS1—endothelium—skin cancer	0.000906	0.0162	CbGeAlD
Doxorubicin—NDUFS2—hair follicle—skin cancer	0.000885	0.0158	CbGeAlD
Doxorubicin—NDUFS3—hair follicle—skin cancer	0.000874	0.0156	CbGeAlD
Doxorubicin—NOS1—blood vessel—skin cancer	0.000835	0.0149	CbGeAlD
Doxorubicin—DHCR7—hair follicle—skin cancer	0.000831	0.0149	CbGeAlD
Doxorubicin—AKR1A1—nipple—skin cancer	0.000797	0.0143	CbGeAlD
Doxorubicin—SLC22A16—female reproductive system—skin cancer	0.00069	0.0123	CbGeAlD
Doxorubicin—NOS3—endothelium—skin cancer	0.000689	0.0123	CbGeAlD
Doxorubicin—RALBP1—hair follicle—skin cancer	0.000688	0.0123	CbGeAlD
Doxorubicin—NOS3—blood vessel—skin cancer	0.000635	0.0114	CbGeAlD
Doxorubicin—CBR3—mammalian vulva—skin cancer	0.000603	0.0108	CbGeAlD
Doxorubicin—NDUFS2—nipple—skin cancer	0.0006	0.0107	CbGeAlD
Doxorubicin—NDUFS3—nipple—skin cancer	0.000593	0.0106	CbGeAlD
Doxorubicin—DHCR7—nipple—skin cancer	0.000563	0.0101	CbGeAlD
Doxorubicin—ABCB8—female reproductive system—skin cancer	0.000536	0.0096	CbGeAlD
Doxorubicin—YWHAG—nipple—skin cancer	0.000517	0.00925	CbGeAlD
Doxorubicin—CBR3—female reproductive system—skin cancer	0.000516	0.00924	CbGeAlD
Doxorubicin—NDUFS7—connective tissue—skin cancer	0.000514	0.00919	CbGeAlD
Doxorubicin—AKR1A1—skin of body—skin cancer	0.00051	0.00913	CbGeAlD
Doxorubicin—RALBP1—nipple—skin cancer	0.000467	0.00835	CbGeAlD
Doxorubicin—AKR1A1—mammalian vulva—skin cancer	0.000465	0.00833	CbGeAlD
Doxorubicin—NOS3—neck—skin cancer	0.000454	0.00813	CbGeAlD
Doxorubicin—ABCB8—head—skin cancer	0.000448	0.00802	CbGeAlD
Doxorubicin—CBR1—nipple—skin cancer	0.000436	0.0078	CbGeAlD
Doxorubicin—CBR3—head—skin cancer	0.000431	0.00772	CbGeAlD
Doxorubicin—AKR1C3—nipple—skin cancer	0.00043	0.0077	CbGeAlD
Doxorubicin—NDUFS2—connective tissue—skin cancer	0.000426	0.00762	CbGeAlD
Doxorubicin—NDUFS3—connective tissue—skin cancer	0.00042	0.00752	CbGeAlD
Doxorubicin—AKR1A1—lymphoid tissue—skin cancer	0.000413	0.00739	CbGeAlD
Doxorubicin—NOS1—epithelium—skin cancer	0.000407	0.00728	CbGeAlD
Doxorubicin—AKR1A1—female reproductive system—skin cancer	0.000399	0.00713	CbGeAlD
Doxorubicin—AURKA—mammalian vulva—skin cancer	0.000393	0.00704	CbGeAlD
Doxorubicin—POR—nipple—skin cancer	0.000393	0.00703	CbGeAlD
Doxorubicin—ABCC6—connective tissue—skin cancer	0.000389	0.00697	CbGeAlD
Doxorubicin—NDUFS2—skin of body—skin cancer	0.000384	0.00688	CbGeAlD
Doxorubicin—NDUFS3—skin of body—skin cancer	0.00038	0.00679	CbGeAlD
Doxorubicin—YWHAG—connective tissue—skin cancer	0.000367	0.00656	CbGeAlD
Doxorubicin—TOP2A—nipple—skin cancer	0.000366	0.00655	CbGeAlD
Doxorubicin—TOP2A—Sorafenib—Vismodegib—skin cancer	0.000364	0.231	CbGdCrCtD
Doxorubicin—NDUFS7—female reproductive system—skin cancer	0.000362	0.00648	CbGeAlD
Doxorubicin—CYP1B1—hair follicle—skin cancer	0.000362	0.00647	CbGeAlD
Doxorubicin—DHCR7—skin of body—skin cancer	0.000361	0.00645	CbGeAlD
Doxorubicin—NDUFS2—mammalian vulva—skin cancer	0.00035	0.00627	CbGeAlD
Doxorubicin—AURKA—lymphoid tissue—skin cancer	0.000349	0.00625	CbGeAlD
Doxorubicin—NQO1—nipple—skin cancer	0.000349	0.00625	CbGeAlD
Doxorubicin—NDUFS3—mammalian vulva—skin cancer	0.000346	0.0062	CbGeAlD
Doxorubicin—NQO1—neck—skin cancer	0.000345	0.00618	CbGeAlD
Doxorubicin—AURKA—female reproductive system—skin cancer	0.000337	0.00603	CbGeAlD
Doxorubicin—AKR1A1—head—skin cancer	0.000333	0.00596	CbGeAlD
Doxorubicin—DHCR7—mammalian vulva—skin cancer	0.000329	0.00589	CbGeAlD
Doxorubicin—NOS3—connective tissue—skin cancer	0.000326	0.00583	CbGeAlD
Doxorubicin—ABCC1—hair follicle—skin cancer	0.000325	0.00582	CbGeAlD
Doxorubicin—ABCB8—lymph node—skin cancer	0.000314	0.00561	CbGeAlD
Doxorubicin—ABCC10—nipple—skin cancer	0.000312	0.00558	CbGeAlD
Doxorubicin—NDUFS2—lymphoid tissue—skin cancer	0.000311	0.00557	CbGeAlD
Doxorubicin—NOS3—epithelium—skin cancer	0.000309	0.00553	CbGeAlD
Doxorubicin—NDUFS3—lymphoid tissue—skin cancer	0.000307	0.0055	CbGeAlD
Doxorubicin—NDUFS7—head—skin cancer	0.000303	0.00542	CbGeAlD
Doxorubicin—NOS1—female reproductive system—skin cancer	0.000302	0.0054	CbGeAlD
Doxorubicin—CBR3—lymph node—skin cancer	0.000302	0.0054	CbGeAlD
Doxorubicin—YWHAG—mammalian vulva—skin cancer	0.000302	0.0054	CbGeAlD
Doxorubicin—NDUFS2—female reproductive system—skin cancer	0.0003	0.00537	CbGeAlD
Doxorubicin—NDUFS3—female reproductive system—skin cancer	0.000296	0.00531	CbGeAlD
Doxorubicin—XDH—mammalian vulva—skin cancer	0.000294	0.00527	CbGeAlD
Doxorubicin—DHCR7—lymphoid tissue—skin cancer	0.000292	0.00523	CbGeAlD
Doxorubicin—DHCR7—female reproductive system—skin cancer	0.000282	0.00504	CbGeAlD
Doxorubicin—AURKA—head—skin cancer	0.000281	0.00503	CbGeAlD
Doxorubicin—CBR1—skin of body—skin cancer	0.000279	0.00499	CbGeAlD
Doxorubicin—RALBP1—mammalian vulva—skin cancer	0.000273	0.00488	CbGeAlD
Doxorubicin—YWHAG—lymphoid tissue—skin cancer	0.000268	0.0048	CbGeAlD
Doxorubicin—TOP2A—Paclitaxel—Docetaxel—skin cancer	0.000259	0.165	CbGdCrCtD
Doxorubicin—YWHAG—female reproductive system—skin cancer	0.000258	0.00463	CbGeAlD
Doxorubicin—CBR1—mammalian vulva—skin cancer	0.000254	0.00455	CbGeAlD
Doxorubicin—NOS1—head—skin cancer	0.000252	0.00452	CbGeAlD
Doxorubicin—XDH—female reproductive system—skin cancer	0.000252	0.00451	CbGeAlD
Doxorubicin—AKR1C3—mammalian vulva—skin cancer	0.000251	0.0045	CbGeAlD
Doxorubicin—NDUFS2—head—skin cancer	0.000251	0.00449	CbGeAlD
Doxorubicin—NDUFS3—head—skin cancer	0.000248	0.00443	CbGeAlD
Doxorubicin—NQO1—connective tissue—skin cancer	0.000248	0.00443	CbGeAlD
Doxorubicin—NOS3—lymphoid tissue—skin cancer	0.000238	0.00426	CbGeAlD
Doxorubicin—DHCR7—head—skin cancer	0.000235	0.00421	CbGeAlD
Doxorubicin—NQO1—epithelium—skin cancer	0.000235	0.00421	CbGeAlD
Doxorubicin—RALBP1—female reproductive system—skin cancer	0.000233	0.00418	CbGeAlD
Doxorubicin—AKR1A1—lymph node—skin cancer	0.000233	0.00417	CbGeAlD
Doxorubicin—NOS3—female reproductive system—skin cancer	0.00023	0.00411	CbGeAlD
Doxorubicin—POR—mammalian vulva—skin cancer	0.000229	0.00411	CbGeAlD
Doxorubicin—ABCC6—head—skin cancer	0.000229	0.0041	CbGeAlD
Doxorubicin—CBR1—lymphoid tissue—skin cancer	0.000226	0.00404	CbGeAlD
Doxorubicin—NQO1—skin of body—skin cancer	0.000224	0.004	CbGeAlD
Doxorubicin—ABCC1—nipple—skin cancer	0.000221	0.00395	CbGeAlD
Doxorubicin—CBR1—female reproductive system—skin cancer	0.000218	0.0039	CbGeAlD
Doxorubicin—YWHAG—head—skin cancer	0.000216	0.00386	CbGeAlD
Doxorubicin—TOP2A—mammalian vulva—skin cancer	0.000214	0.00383	CbGeAlD
Doxorubicin—NDUFS7—lymph node—skin cancer	0.000212	0.00379	CbGeAlD
Doxorubicin—NQO1—mammalian vulva—skin cancer	0.000204	0.00365	CbGeAlD
Doxorubicin—AURKA—lymph node—skin cancer	0.000197	0.00353	CbGeAlD
Doxorubicin—RALBP1—head—skin cancer	0.000195	0.00349	CbGeAlD
Doxorubicin—NOS3—head—skin cancer	0.000192	0.00343	CbGeAlD
Doxorubicin—ABCC10—mammalian vulva—skin cancer	0.000182	0.00326	CbGeAlD
Doxorubicin—CBR1—head—skin cancer	0.000182	0.00326	CbGeAlD
Doxorubicin—NDUFS2—lymph node—skin cancer	0.000176	0.00314	CbGeAlD
Doxorubicin—NQO1—female reproductive system—skin cancer	0.000175	0.00312	CbGeAlD
Doxorubicin—CYP1B1—connective tissue—skin cancer	0.000174	0.00311	CbGeAlD
Doxorubicin—NDUFS3—lymph node—skin cancer	0.000173	0.0031	CbGeAlD
Doxorubicin—DHCR7—lymph node—skin cancer	0.000165	0.00295	CbGeAlD
Doxorubicin—ABCC10—lymphoid tissue—skin cancer	0.000162	0.00289	CbGeAlD
Doxorubicin—CYP1B1—skin of body—skin cancer	0.000157	0.00281	CbGeAlD
Doxorubicin—ABCC3—female reproductive system—skin cancer	0.000157	0.0028	CbGeAlD
Doxorubicin—ABCC10—female reproductive system—skin cancer	0.000156	0.00279	CbGeAlD
Doxorubicin—YWHAG—lymph node—skin cancer	0.000151	0.00271	CbGeAlD
Doxorubicin—NQO1—head—skin cancer	0.000146	0.00261	CbGeAlD
Doxorubicin—RALBP1—lymph node—skin cancer	0.000137	0.00244	CbGeAlD
Doxorubicin—NOS3—lymph node—skin cancer	0.000134	0.0024	CbGeAlD
Doxorubicin—ABCC3—head—skin cancer	0.000131	0.00234	CbGeAlD
Doxorubicin—ABCC1—mammalian vulva—skin cancer	0.000129	0.0023	CbGeAlD
Doxorubicin—CBR1—lymph node—skin cancer	0.000127	0.00228	CbGeAlD
Doxorubicin—CYP1B1—lymphoid tissue—skin cancer	0.000127	0.00227	CbGeAlD
Doxorubicin—AKR1C3—lymph node—skin cancer	0.000126	0.00225	CbGeAlD
Doxorubicin—ABCC2—female reproductive system—skin cancer	0.000125	0.00224	CbGeAlD
Doxorubicin—ABCB1—blood vessel—skin cancer	0.000125	0.00223	CbGeAlD
Doxorubicin—CYP1B1—female reproductive system—skin cancer	0.000123	0.00219	CbGeAlD
Doxorubicin—POR—lymph node—skin cancer	0.000115	0.00206	CbGeAlD
Doxorubicin—CYP2B6—skin of body—skin cancer	0.000108	0.00193	CbGeAlD
Doxorubicin—TOP2A—lymph node—skin cancer	0.000107	0.00192	CbGeAlD
Doxorubicin—ABCG2—mammalian vulva—skin cancer	0.000107	0.00191	CbGeAlD
Doxorubicin—CYP1B1—head—skin cancer	0.000102	0.00183	CbGeAlD
Doxorubicin—NQO1—lymph node—skin cancer	0.000102	0.00183	CbGeAlD
Doxorubicin—ABCC3—lymph node—skin cancer	9.17e-05	0.00164	CbGeAlD
Doxorubicin—ABCC10—lymph node—skin cancer	9.12e-05	0.00163	CbGeAlD
Doxorubicin—CYP2B6—lymphoid tissue—skin cancer	8.73e-05	0.00156	CbGeAlD
Doxorubicin—CYP2B6—female reproductive system—skin cancer	8.42e-05	0.00151	CbGeAlD
Doxorubicin—ABCC2—lymph node—skin cancer	7.32e-05	0.00131	CbGeAlD
Doxorubicin—CYP1B1—lymph node—skin cancer	7.17e-05	0.00128	CbGeAlD
Doxorubicin—CYP2B6—head—skin cancer	7.04e-05	0.00126	CbGeAlD
Doxorubicin—ABCC1—lymph node—skin cancer	6.45e-05	0.00115	CbGeAlD
Doxorubicin—CYP3A4—female reproductive system—skin cancer	6.36e-05	0.00114	CbGeAlD
Doxorubicin—CYP2D6—female reproductive system—skin cancer	6.26e-05	0.00112	CbGeAlD
Doxorubicin—ABCB1—epithelium—skin cancer	6.06e-05	0.00108	CbGeAlD
Doxorubicin—ABCG2—lymph node—skin cancer	5.34e-05	0.000956	CbGeAlD
Doxorubicin—ABCB1—mammalian vulva—skin cancer	5.26e-05	0.000941	CbGeAlD
Doxorubicin—CYP2D6—head—skin cancer	5.23e-05	0.000936	CbGeAlD
Doxorubicin—Erythema—Temozolomide—skin cancer	5.23e-05	0.000482	CcSEcCtD
Doxorubicin—Malnutrition—Temozolomide—skin cancer	5.23e-05	0.000482	CcSEcCtD
Doxorubicin—Breast disorder—Docetaxel—skin cancer	5.22e-05	0.000481	CcSEcCtD
Doxorubicin—Discomfort—Bleomycin—skin cancer	5.21e-05	0.00048	CcSEcCtD
Doxorubicin—Malaise—Dactinomycin—skin cancer	5.21e-05	0.00048	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Docetaxel—skin cancer	5.2e-05	0.000479	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Docetaxel—skin cancer	5.2e-05	0.000479	CcSEcCtD
Doxorubicin—Leukopenia—Dactinomycin—skin cancer	5.17e-05	0.000477	CcSEcCtD
Doxorubicin—Nasopharyngitis—Docetaxel—skin cancer	5.16e-05	0.000476	CcSEcCtD
Doxorubicin—Dysgeusia—Temozolomide—skin cancer	5.12e-05	0.000472	CcSEcCtD
Doxorubicin—Asthenia—Imiquimod—skin cancer	5.11e-05	0.000471	CcSEcCtD
Doxorubicin—Confusional state—Bleomycin—skin cancer	5.1e-05	0.00047	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Docetaxel—skin cancer	5.09e-05	0.000469	CcSEcCtD
Doxorubicin—Anaphylactic shock—Bleomycin—skin cancer	5.06e-05	0.000466	CcSEcCtD
Doxorubicin—Oedema—Bleomycin—skin cancer	5.06e-05	0.000466	CcSEcCtD
Doxorubicin—Back pain—Temozolomide—skin cancer	5.06e-05	0.000466	CcSEcCtD
Doxorubicin—Pruritus—Imiquimod—skin cancer	5.04e-05	0.000464	CcSEcCtD
Doxorubicin—Infection—Bleomycin—skin cancer	5.03e-05	0.000463	CcSEcCtD
Doxorubicin—Dysphagia—Docetaxel—skin cancer	4.99e-05	0.00046	CcSEcCtD
Doxorubicin—Nausea—Vemurafenib—skin cancer	4.96e-05	0.000457	CcSEcCtD
Doxorubicin—Thrombocytopenia—Bleomycin—skin cancer	4.95e-05	0.000456	CcSEcCtD
Doxorubicin—Arrhythmia—Fluorouracil—skin cancer	4.94e-05	0.000456	CcSEcCtD
Doxorubicin—Vision blurred—Temozolomide—skin cancer	4.93e-05	0.000454	CcSEcCtD
Doxorubicin—Myalgia—Dactinomycin—skin cancer	4.92e-05	0.000454	CcSEcCtD
Doxorubicin—Alopecia—Fluorouracil—skin cancer	4.89e-05	0.000451	CcSEcCtD
Doxorubicin—Diarrhoea—Imiquimod—skin cancer	4.87e-05	0.000449	CcSEcCtD
Doxorubicin—Discomfort—Dactinomycin—skin cancer	4.86e-05	0.000448	CcSEcCtD
Doxorubicin—Angina pectoris—Docetaxel—skin cancer	4.86e-05	0.000448	CcSEcCtD
Doxorubicin—Ill-defined disorder—Temozolomide—skin cancer	4.85e-05	0.000447	CcSEcCtD
Doxorubicin—Anaemia—Temozolomide—skin cancer	4.83e-05	0.000445	CcSEcCtD
Doxorubicin—Anorexia—Bleomycin—skin cancer	4.82e-05	0.000444	CcSEcCtD
Doxorubicin—Erythema—Fluorouracil—skin cancer	4.82e-05	0.000444	CcSEcCtD
Doxorubicin—Agitation—Temozolomide—skin cancer	4.81e-05	0.000443	CcSEcCtD
Doxorubicin—Pancytopenia—Docetaxel—skin cancer	4.74e-05	0.000437	CcSEcCtD
Doxorubicin—Hypotension—Bleomycin—skin cancer	4.73e-05	0.000436	CcSEcCtD
Doxorubicin—Oedema—Dactinomycin—skin cancer	4.72e-05	0.000435	CcSEcCtD
Doxorubicin—Malaise—Temozolomide—skin cancer	4.72e-05	0.000434	CcSEcCtD
Doxorubicin—Dizziness—Imiquimod—skin cancer	4.71e-05	0.000434	CcSEcCtD
Doxorubicin—Vertigo—Temozolomide—skin cancer	4.7e-05	0.000433	CcSEcCtD
Doxorubicin—Infection—Dactinomycin—skin cancer	4.69e-05	0.000432	CcSEcCtD
Doxorubicin—Leukopenia—Temozolomide—skin cancer	4.68e-05	0.000431	CcSEcCtD
Doxorubicin—ABCB1—lymphoid tissue—skin cancer	4.67e-05	0.000835	CbGeAlD
Doxorubicin—Neutropenia—Docetaxel—skin cancer	4.67e-05	0.00043	CcSEcCtD
Doxorubicin—Palpitations—Temozolomide—skin cancer	4.62e-05	0.000426	CcSEcCtD
Doxorubicin—Thrombocytopenia—Dactinomycin—skin cancer	4.62e-05	0.000426	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Bleomycin—skin cancer	4.61e-05	0.000425	CcSEcCtD
Doxorubicin—Cough—Temozolomide—skin cancer	4.56e-05	0.00042	CcSEcCtD
Doxorubicin—Paraesthesia—Bleomycin—skin cancer	4.54e-05	0.000419	CcSEcCtD
Doxorubicin—Weight increased—Docetaxel—skin cancer	4.54e-05	0.000418	CcSEcCtD
Doxorubicin—Vision blurred—Fluorouracil—skin cancer	4.54e-05	0.000418	CcSEcCtD
Doxorubicin—Convulsion—Temozolomide—skin cancer	4.53e-05	0.000417	CcSEcCtD
Doxorubicin—Vomiting—Imiquimod—skin cancer	4.53e-05	0.000417	CcSEcCtD
Doxorubicin—Weight decreased—Docetaxel—skin cancer	4.52e-05	0.000416	CcSEcCtD
Doxorubicin—Hypertension—Temozolomide—skin cancer	4.51e-05	0.000416	CcSEcCtD
Doxorubicin—Dyspnoea—Bleomycin—skin cancer	4.51e-05	0.000416	CcSEcCtD
Doxorubicin—ABCB1—female reproductive system—skin cancer	4.5e-05	0.000806	CbGeAlD
Doxorubicin—Anorexia—Dactinomycin—skin cancer	4.5e-05	0.000414	CcSEcCtD
Doxorubicin—Rash—Imiquimod—skin cancer	4.49e-05	0.000414	CcSEcCtD
Doxorubicin—Dermatitis—Imiquimod—skin cancer	4.49e-05	0.000413	CcSEcCtD
Doxorubicin—Pneumonia—Docetaxel—skin cancer	4.48e-05	0.000412	CcSEcCtD
Doxorubicin—Headache—Imiquimod—skin cancer	4.46e-05	0.000411	CcSEcCtD
Doxorubicin—Anaemia—Fluorouracil—skin cancer	4.45e-05	0.00041	CcSEcCtD
Doxorubicin—Myalgia—Temozolomide—skin cancer	4.45e-05	0.00041	CcSEcCtD
Doxorubicin—Arthralgia—Temozolomide—skin cancer	4.45e-05	0.00041	CcSEcCtD
Doxorubicin—Infestation—Docetaxel—skin cancer	4.45e-05	0.00041	CcSEcCtD
Doxorubicin—Infestation NOS—Docetaxel—skin cancer	4.45e-05	0.00041	CcSEcCtD
Doxorubicin—Anxiety—Temozolomide—skin cancer	4.44e-05	0.000409	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	4.42e-05	0.000407	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Docetaxel—skin cancer	4.41e-05	0.000406	CcSEcCtD
Doxorubicin—Discomfort—Temozolomide—skin cancer	4.4e-05	0.000405	CcSEcCtD
Doxorubicin—Decreased appetite—Bleomycin—skin cancer	4.4e-05	0.000405	CcSEcCtD
Doxorubicin—Renal failure—Docetaxel—skin cancer	4.37e-05	0.000403	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Docetaxel—skin cancer	4.36e-05	0.000402	CcSEcCtD
Doxorubicin—Dry mouth—Temozolomide—skin cancer	4.35e-05	0.000401	CcSEcCtD
Doxorubicin—Stomatitis—Docetaxel—skin cancer	4.34e-05	0.0004	CcSEcCtD
Doxorubicin—Jaundice—Docetaxel—skin cancer	4.34e-05	0.0004	CcSEcCtD
Doxorubicin—Pain—Bleomycin—skin cancer	4.33e-05	0.000399	CcSEcCtD
Doxorubicin—Conjunctivitis—Docetaxel—skin cancer	4.33e-05	0.000399	CcSEcCtD
Doxorubicin—Leukopenia—Fluorouracil—skin cancer	4.31e-05	0.000397	CcSEcCtD
Doxorubicin—Confusional state—Temozolomide—skin cancer	4.3e-05	0.000396	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Dactinomycin—skin cancer	4.3e-05	0.000396	CcSEcCtD
Doxorubicin—Anaphylactic shock—Temozolomide—skin cancer	4.27e-05	0.000393	CcSEcCtD
Doxorubicin—Oedema—Temozolomide—skin cancer	4.27e-05	0.000393	CcSEcCtD
Doxorubicin—Infection—Temozolomide—skin cancer	4.24e-05	0.000391	CcSEcCtD
Doxorubicin—Nausea—Imiquimod—skin cancer	4.23e-05	0.00039	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Docetaxel—skin cancer	4.21e-05	0.000388	CcSEcCtD
Doxorubicin—Epistaxis—Docetaxel—skin cancer	4.2e-05	0.000387	CcSEcCtD
Doxorubicin—Nervous system disorder—Temozolomide—skin cancer	4.19e-05	0.000386	CcSEcCtD
Doxorubicin—Thrombocytopenia—Temozolomide—skin cancer	4.18e-05	0.000385	CcSEcCtD
Doxorubicin—Convulsion—Fluorouracil—skin cancer	4.17e-05	0.000385	CcSEcCtD
Doxorubicin—Feeling abnormal—Bleomycin—skin cancer	4.17e-05	0.000384	CcSEcCtD
Doxorubicin—Agranulocytosis—Docetaxel—skin cancer	4.15e-05	0.000383	CcSEcCtD
Doxorubicin—Skin disorder—Temozolomide—skin cancer	4.15e-05	0.000382	CcSEcCtD
Doxorubicin—Hyperhidrosis—Temozolomide—skin cancer	4.13e-05	0.00038	CcSEcCtD
Doxorubicin—Chest pain—Fluorouracil—skin cancer	4.1e-05	0.000378	CcSEcCtD
Doxorubicin—Myalgia—Fluorouracil—skin cancer	4.1e-05	0.000378	CcSEcCtD
Doxorubicin—Decreased appetite—Dactinomycin—skin cancer	4.1e-05	0.000378	CcSEcCtD
Doxorubicin—Fatigue—Dactinomycin—skin cancer	4.07e-05	0.000375	CcSEcCtD
Doxorubicin—Anorexia—Temozolomide—skin cancer	4.07e-05	0.000375	CcSEcCtD
Doxorubicin—Discomfort—Fluorouracil—skin cancer	4.05e-05	0.000373	CcSEcCtD
Doxorubicin—Pain—Dactinomycin—skin cancer	4.03e-05	0.000372	CcSEcCtD
Doxorubicin—Urticaria—Bleomycin—skin cancer	4.02e-05	0.00037	CcSEcCtD
Doxorubicin—Haemoglobin—Docetaxel—skin cancer	4.01e-05	0.00037	CcSEcCtD
Doxorubicin—Rhinitis—Docetaxel—skin cancer	4e-05	0.000369	CcSEcCtD
Doxorubicin—Body temperature increased—Bleomycin—skin cancer	4e-05	0.000368	CcSEcCtD
Doxorubicin—Haemorrhage—Docetaxel—skin cancer	3.99e-05	0.000368	CcSEcCtD
Doxorubicin—Hepatitis—Docetaxel—skin cancer	3.99e-05	0.000368	CcSEcCtD
Doxorubicin—Hypoaesthesia—Docetaxel—skin cancer	3.97e-05	0.000366	CcSEcCtD
Doxorubicin—Confusional state—Fluorouracil—skin cancer	3.96e-05	0.000365	CcSEcCtD
Doxorubicin—Pharyngitis—Docetaxel—skin cancer	3.96e-05	0.000365	CcSEcCtD
Doxorubicin—Urinary tract disorder—Docetaxel—skin cancer	3.94e-05	0.000363	CcSEcCtD
Doxorubicin—Oedema peripheral—Docetaxel—skin cancer	3.94e-05	0.000363	CcSEcCtD
Doxorubicin—Anaphylactic shock—Fluorouracil—skin cancer	3.93e-05	0.000362	CcSEcCtD
Doxorubicin—Oedema—Fluorouracil—skin cancer	3.93e-05	0.000362	CcSEcCtD
Doxorubicin—Connective tissue disorder—Docetaxel—skin cancer	3.93e-05	0.000362	CcSEcCtD
Doxorubicin—Urethral disorder—Docetaxel—skin cancer	3.92e-05	0.000361	CcSEcCtD
Doxorubicin—Infection—Fluorouracil—skin cancer	3.91e-05	0.00036	CcSEcCtD
Doxorubicin—Feeling abnormal—Dactinomycin—skin cancer	3.89e-05	0.000358	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Temozolomide—skin cancer	3.89e-05	0.000358	CcSEcCtD
Doxorubicin—Insomnia—Temozolomide—skin cancer	3.86e-05	0.000356	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dactinomycin—skin cancer	3.86e-05	0.000356	CcSEcCtD
Doxorubicin—Nervous system disorder—Fluorouracil—skin cancer	3.86e-05	0.000355	CcSEcCtD
Doxorubicin—Thrombocytopenia—Fluorouracil—skin cancer	3.85e-05	0.000355	CcSEcCtD
Doxorubicin—Visual impairment—Docetaxel—skin cancer	3.85e-05	0.000355	CcSEcCtD
Doxorubicin—Tachycardia—Fluorouracil—skin cancer	3.84e-05	0.000354	CcSEcCtD
Doxorubicin—Paraesthesia—Temozolomide—skin cancer	3.83e-05	0.000353	CcSEcCtD
Doxorubicin—Dyspnoea—Temozolomide—skin cancer	3.8e-05	0.000351	CcSEcCtD
Doxorubicin—Somnolence—Temozolomide—skin cancer	3.79e-05	0.00035	CcSEcCtD
Doxorubicin—Erythema multiforme—Docetaxel—skin cancer	3.78e-05	0.000348	CcSEcCtD
Doxorubicin—ABCB1—head—skin cancer	3.76e-05	0.000673	CbGeAlD
Doxorubicin—Dyspepsia—Temozolomide—skin cancer	3.76e-05	0.000346	CcSEcCtD
Doxorubicin—Anorexia—Fluorouracil—skin cancer	3.75e-05	0.000345	CcSEcCtD
Doxorubicin—Eye disorder—Docetaxel—skin cancer	3.73e-05	0.000344	CcSEcCtD
Doxorubicin—Abdominal pain—Dactinomycin—skin cancer	3.73e-05	0.000344	CcSEcCtD
Doxorubicin—Body temperature increased—Dactinomycin—skin cancer	3.73e-05	0.000344	CcSEcCtD
Doxorubicin—Hypersensitivity—Bleomycin—skin cancer	3.73e-05	0.000343	CcSEcCtD
Doxorubicin—Decreased appetite—Temozolomide—skin cancer	3.71e-05	0.000342	CcSEcCtD
Doxorubicin—Cardiac disorder—Docetaxel—skin cancer	3.71e-05	0.000342	CcSEcCtD
Doxorubicin—Flushing—Docetaxel—skin cancer	3.71e-05	0.000342	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Temozolomide—skin cancer	3.68e-05	0.000339	CcSEcCtD
Doxorubicin—Fatigue—Temozolomide—skin cancer	3.68e-05	0.000339	CcSEcCtD
Doxorubicin—Hypotension—Fluorouracil—skin cancer	3.67e-05	0.000339	CcSEcCtD
Doxorubicin—Pain—Temozolomide—skin cancer	3.65e-05	0.000336	CcSEcCtD
Doxorubicin—Constipation—Temozolomide—skin cancer	3.65e-05	0.000336	CcSEcCtD
Doxorubicin—Asthenia—Bleomycin—skin cancer	3.63e-05	0.000334	CcSEcCtD
Doxorubicin—Angiopathy—Docetaxel—skin cancer	3.62e-05	0.000334	CcSEcCtD
Doxorubicin—Immune system disorder—Docetaxel—skin cancer	3.61e-05	0.000332	CcSEcCtD
Doxorubicin—Mediastinal disorder—Docetaxel—skin cancer	3.6e-05	0.000332	CcSEcCtD
Doxorubicin—Chills—Docetaxel—skin cancer	3.58e-05	0.00033	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Fluorouracil—skin cancer	3.58e-05	0.00033	CcSEcCtD
Doxorubicin—Pruritus—Bleomycin—skin cancer	3.58e-05	0.00033	CcSEcCtD
Doxorubicin—Arrhythmia—Docetaxel—skin cancer	3.57e-05	0.000329	CcSEcCtD
Doxorubicin—Insomnia—Fluorouracil—skin cancer	3.56e-05	0.000328	CcSEcCtD
Doxorubicin—Paraesthesia—Fluorouracil—skin cancer	3.53e-05	0.000325	CcSEcCtD
Doxorubicin—Alopecia—Docetaxel—skin cancer	3.53e-05	0.000325	CcSEcCtD
Doxorubicin—Feeling abnormal—Temozolomide—skin cancer	3.52e-05	0.000324	CcSEcCtD
Doxorubicin—Dyspnoea—Fluorouracil—skin cancer	3.51e-05	0.000323	CcSEcCtD
Doxorubicin—Mental disorder—Docetaxel—skin cancer	3.5e-05	0.000322	CcSEcCtD
Doxorubicin—Somnolence—Fluorouracil—skin cancer	3.5e-05	0.000322	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Temozolomide—skin cancer	3.49e-05	0.000322	CcSEcCtD
Doxorubicin—Erythema—Docetaxel—skin cancer	3.48e-05	0.00032	CcSEcCtD
Doxorubicin—Malnutrition—Docetaxel—skin cancer	3.48e-05	0.00032	CcSEcCtD
Doxorubicin—Hypersensitivity—Dactinomycin—skin cancer	3.48e-05	0.00032	CcSEcCtD
Doxorubicin—Dyspepsia—Fluorouracil—skin cancer	3.46e-05	0.000319	CcSEcCtD
Doxorubicin—Decreased appetite—Fluorouracil—skin cancer	3.42e-05	0.000315	CcSEcCtD
Doxorubicin—Dysgeusia—Docetaxel—skin cancer	3.41e-05	0.000314	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Fluorouracil—skin cancer	3.39e-05	0.000313	CcSEcCtD
Doxorubicin—Urticaria—Temozolomide—skin cancer	3.39e-05	0.000312	CcSEcCtD
Doxorubicin—Asthenia—Dactinomycin—skin cancer	3.39e-05	0.000312	CcSEcCtD
Doxorubicin—Abdominal pain—Temozolomide—skin cancer	3.37e-05	0.000311	CcSEcCtD
Doxorubicin—Body temperature increased—Temozolomide—skin cancer	3.37e-05	0.000311	CcSEcCtD
Doxorubicin—Back pain—Docetaxel—skin cancer	3.36e-05	0.00031	CcSEcCtD
Doxorubicin—Pain—Fluorouracil—skin cancer	3.36e-05	0.00031	CcSEcCtD
Doxorubicin—Muscle spasms—Docetaxel—skin cancer	3.34e-05	0.000308	CcSEcCtD
Doxorubicin—AKR1C3—Disease—CSPG4—skin cancer	3.26e-05	0.000895	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Fluorouracil—skin cancer	3.24e-05	0.000299	CcSEcCtD
Doxorubicin—Diarrhoea—Dactinomycin—skin cancer	3.23e-05	0.000297	CcSEcCtD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	3.23e-05	0.000886	CbGpPWpGaD
Doxorubicin—Vomiting—Bleomycin—skin cancer	3.22e-05	0.000296	CcSEcCtD
Doxorubicin—Anaemia—Docetaxel—skin cancer	3.21e-05	0.000296	CcSEcCtD
Doxorubicin—NOS1—Disease—ENO2—skin cancer	3.2e-05	0.000878	CbGpPWpGaD
Doxorubicin—NOS1—Disease—SHH—skin cancer	3.2e-05	0.000878	CbGpPWpGaD
Doxorubicin—Rash—Bleomycin—skin cancer	3.19e-05	0.000294	CcSEcCtD
Doxorubicin—Dermatitis—Bleomycin—skin cancer	3.19e-05	0.000294	CcSEcCtD
Doxorubicin—AURKA—EGF/EGFR Signaling Pathway—HRAS—skin cancer	3.17e-05	0.00087	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PLIN2—skin cancer	3.15e-05	0.000864	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Temozolomide—skin cancer	3.14e-05	0.00029	CcSEcCtD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	3.12e-05	0.000858	CbGpPWpGaD
Doxorubicin—Urticaria—Fluorouracil—skin cancer	3.12e-05	0.000288	CcSEcCtD
Doxorubicin—Syncope—Docetaxel—skin cancer	3.12e-05	0.000287	CcSEcCtD
Doxorubicin—Leukopenia—Docetaxel—skin cancer	3.11e-05	0.000287	CcSEcCtD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	3.11e-05	0.000855	CbGpPWpGaD
Doxorubicin—Body temperature increased—Fluorouracil—skin cancer	3.11e-05	0.000286	CcSEcCtD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.1e-05	0.000853	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—MLH1—skin cancer	3.08e-05	0.000846	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	3.08e-05	0.000845	CbGpPWpGaD
Doxorubicin—Palpitations—Docetaxel—skin cancer	3.07e-05	0.000283	CcSEcCtD
Doxorubicin—Asthenia—Temozolomide—skin cancer	3.06e-05	0.000282	CcSEcCtD
Doxorubicin—Loss of consciousness—Docetaxel—skin cancer	3.06e-05	0.000282	CcSEcCtD
Doxorubicin—Cough—Docetaxel—skin cancer	3.03e-05	0.00028	CcSEcCtD
Doxorubicin—NOS2—Spinal Cord Injury—IL6—skin cancer	3.03e-05	0.000832	CbGpPWpGaD
Doxorubicin—Pruritus—Temozolomide—skin cancer	3.02e-05	0.000278	CcSEcCtD
Doxorubicin—Convulsion—Docetaxel—skin cancer	3.01e-05	0.000278	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—PTCH2—skin cancer	3.01e-05	0.000827	CbGpPWpGaD
Doxorubicin—Nausea—Bleomycin—skin cancer	3.01e-05	0.000277	CcSEcCtD
Doxorubicin—Hypertension—Docetaxel—skin cancer	3e-05	0.000277	CcSEcCtD
Doxorubicin—Vomiting—Dactinomycin—skin cancer	3e-05	0.000276	CcSEcCtD
Doxorubicin—Rash—Dactinomycin—skin cancer	2.97e-05	0.000274	CcSEcCtD
Doxorubicin—Myalgia—Docetaxel—skin cancer	2.96e-05	0.000273	CcSEcCtD
Doxorubicin—Chest pain—Docetaxel—skin cancer	2.96e-05	0.000273	CcSEcCtD
Doxorubicin—Arthralgia—Docetaxel—skin cancer	2.96e-05	0.000273	CcSEcCtD
Doxorubicin—AURKA—Cell Cycle—CDK4—skin cancer	2.95e-05	0.000811	CbGpPWpGaD
Doxorubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—skin cancer	2.95e-05	0.000811	CbGpPWpGaD
Doxorubicin—NOS3—Signaling by VEGF—KRAS—skin cancer	2.95e-05	0.00081	CbGpPWpGaD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	2.94e-05	0.000271	CcSEcCtD
Doxorubicin—Diarrhoea—Temozolomide—skin cancer	2.92e-05	0.000269	CcSEcCtD
Doxorubicin—Hypersensitivity—Fluorouracil—skin cancer	2.9e-05	0.000267	CcSEcCtD
Doxorubicin—Dry mouth—Docetaxel—skin cancer	2.9e-05	0.000267	CcSEcCtD
Doxorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—skin cancer	2.88e-05	0.000792	CbGpPWpGaD
Doxorubicin—Confusional state—Docetaxel—skin cancer	2.86e-05	0.000264	CcSEcCtD
Doxorubicin—NOS3—Metabolism—PLIN2—skin cancer	2.86e-05	0.000786	CbGpPWpGaD
Doxorubicin—Anaphylactic shock—Docetaxel—skin cancer	2.84e-05	0.000261	CcSEcCtD
Doxorubicin—Oedema—Docetaxel—skin cancer	2.84e-05	0.000261	CcSEcCtD
Doxorubicin—NQO1—Metabolism—CSPG4—skin cancer	2.83e-05	0.000777	CbGpPWpGaD
Doxorubicin—Dizziness—Temozolomide—skin cancer	2.82e-05	0.00026	CcSEcCtD
Doxorubicin—Infection—Docetaxel—skin cancer	2.82e-05	0.00026	CcSEcCtD
Doxorubicin—Nausea—Dactinomycin—skin cancer	2.8e-05	0.000258	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—SHH—skin cancer	2.8e-05	0.000769	CbGpPWpGaD
Doxorubicin—Shock—Docetaxel—skin cancer	2.79e-05	0.000257	CcSEcCtD
Doxorubicin—Nervous system disorder—Docetaxel—skin cancer	2.78e-05	0.000256	CcSEcCtD
Doxorubicin—Pruritus—Fluorouracil—skin cancer	2.78e-05	0.000256	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—RASA1—skin cancer	2.78e-05	0.000764	CbGpPWpGaD
Doxorubicin—Thrombocytopenia—Docetaxel—skin cancer	2.78e-05	0.000256	CcSEcCtD
Doxorubicin—Tachycardia—Docetaxel—skin cancer	2.77e-05	0.000255	CcSEcCtD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.76e-05	0.000758	CbGpPWpGaD
Doxorubicin—Skin disorder—Docetaxel—skin cancer	2.76e-05	0.000254	CcSEcCtD
Doxorubicin—NOS3—Disease—CSPG4—skin cancer	2.75e-05	0.000756	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—CSPG4—skin cancer	2.73e-05	0.000749	CbGpPWpGaD
Doxorubicin—Vomiting—Temozolomide—skin cancer	2.71e-05	0.00025	CcSEcCtD
Doxorubicin—Anorexia—Docetaxel—skin cancer	2.71e-05	0.000249	CcSEcCtD
Doxorubicin—Rash—Temozolomide—skin cancer	2.69e-05	0.000248	CcSEcCtD
Doxorubicin—Diarrhoea—Fluorouracil—skin cancer	2.69e-05	0.000248	CcSEcCtD
Doxorubicin—Dermatitis—Temozolomide—skin cancer	2.69e-05	0.000248	CcSEcCtD
Doxorubicin—Headache—Temozolomide—skin cancer	2.67e-05	0.000246	CcSEcCtD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	2.66e-05	0.00073	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—SMO—skin cancer	2.65e-05	0.000729	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PTCH1—skin cancer	2.65e-05	0.000729	CbGpPWpGaD
Doxorubicin—Hypotension—Docetaxel—skin cancer	2.65e-05	0.000244	CcSEcCtD
Doxorubicin—ABCB1—lymph node—skin cancer	2.63e-05	0.000471	CbGeAlD
Doxorubicin—NOS1—Disease—FOXO4—skin cancer	2.6e-05	0.000715	CbGpPWpGaD
Doxorubicin—Dizziness—Fluorouracil—skin cancer	2.6e-05	0.00024	CcSEcCtD
Doxorubicin—YWHAG—Apoptosis—TP53—skin cancer	2.6e-05	0.000714	CbGpPWpGaD
Doxorubicin—Musculoskeletal discomfort—Docetaxel—skin cancer	2.59e-05	0.000238	CcSEcCtD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.58e-05	0.00071	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PTGER4—skin cancer	2.58e-05	0.000709	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.58e-05	0.000707	CbGpPWpGaD
Doxorubicin—Insomnia—Docetaxel—skin cancer	2.57e-05	0.000237	CcSEcCtD
Doxorubicin—NDUFS3—Metabolism—ERCC2—skin cancer	2.57e-05	0.000705	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—ERCC2—skin cancer	2.57e-05	0.000705	CbGpPWpGaD
Doxorubicin—Paraesthesia—Docetaxel—skin cancer	2.55e-05	0.000235	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—PTCH2—skin cancer	2.54e-05	0.000699	CbGpPWpGaD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—IL6—skin cancer	2.54e-05	0.000698	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—CSPG4—skin cancer	2.54e-05	0.000697	CbGpPWpGaD
Doxorubicin—Nausea—Temozolomide—skin cancer	2.53e-05	0.000234	CcSEcCtD
Doxorubicin—Dyspnoea—Docetaxel—skin cancer	2.53e-05	0.000233	CcSEcCtD
Doxorubicin—AURKA—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.52e-05	0.000693	CbGpPWpGaD
Doxorubicin—Somnolence—Docetaxel—skin cancer	2.52e-05	0.000232	CcSEcCtD
Doxorubicin—NOS3—Signaling by VEGF—HRAS—skin cancer	2.51e-05	0.000689	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CDK4—skin cancer	2.5e-05	0.000687	CbGpPWpGaD
Doxorubicin—Vomiting—Fluorouracil—skin cancer	2.5e-05	0.00023	CcSEcCtD
Doxorubicin—YWHAG—Cell Cycle—TERT—skin cancer	2.5e-05	0.000687	CbGpPWpGaD
Doxorubicin—Dyspepsia—Docetaxel—skin cancer	2.5e-05	0.00023	CcSEcCtD
Doxorubicin—Rash—Fluorouracil—skin cancer	2.48e-05	0.000228	CcSEcCtD
Doxorubicin—Dermatitis—Fluorouracil—skin cancer	2.48e-05	0.000228	CcSEcCtD
Doxorubicin—Decreased appetite—Docetaxel—skin cancer	2.47e-05	0.000227	CcSEcCtD
Doxorubicin—Headache—Fluorouracil—skin cancer	2.46e-05	0.000227	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Docetaxel—skin cancer	2.45e-05	0.000226	CcSEcCtD
Doxorubicin—Fatigue—Docetaxel—skin cancer	2.45e-05	0.000225	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.44e-05	0.000671	CbGpPWpGaD
Doxorubicin—Pain—Docetaxel—skin cancer	2.43e-05	0.000224	CcSEcCtD
Doxorubicin—Constipation—Docetaxel—skin cancer	2.43e-05	0.000224	CcSEcCtD
Doxorubicin—NDUFS2—Metabolism—ERCC2—skin cancer	2.41e-05	0.000663	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SHH—skin cancer	2.41e-05	0.000662	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ENO2—skin cancer	2.41e-05	0.000662	CbGpPWpGaD
Doxorubicin—NOS3—Signaling by VEGF—IL6—skin cancer	2.4e-05	0.000659	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	2.38e-05	0.000653	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL6—skin cancer	2.37e-05	0.00065	CbGpPWpGaD
Doxorubicin—Feeling abnormal—Docetaxel—skin cancer	2.34e-05	0.000215	CcSEcCtD
Doxorubicin—Nausea—Fluorouracil—skin cancer	2.34e-05	0.000215	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Docetaxel—skin cancer	2.32e-05	0.000214	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—PLIN2—skin cancer	2.32e-05	0.000637	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.32e-05	0.000636	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—CSPG4—skin cancer	2.31e-05	0.000633	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—GLI2—skin cancer	2.28e-05	0.000627	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—FOXO4—skin cancer	2.28e-05	0.000627	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—CDKN2A—skin cancer	2.26e-05	0.00062	CbGpPWpGaD
Doxorubicin—Abdominal pain—Docetaxel—skin cancer	2.24e-05	0.000207	CcSEcCtD
Doxorubicin—Body temperature increased—Docetaxel—skin cancer	2.24e-05	0.000207	CcSEcCtD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—KRAS—skin cancer	2.24e-05	0.000616	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—CDK4—skin cancer	2.24e-05	0.000615	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PLIN2—skin cancer	2.22e-05	0.000611	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—ENO2—skin cancer	2.21e-05	0.000608	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SHH—skin cancer	2.21e-05	0.000608	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MC1R—skin cancer	2.18e-05	0.000598	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—TP53—skin cancer	2.16e-05	0.000593	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—GLI1—skin cancer	2.15e-05	0.000589	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Docetaxel—skin cancer	2.09e-05	0.000193	CcSEcCtD
Doxorubicin—DHCR7—Metabolism—ERCC2—skin cancer	2.05e-05	0.000563	CbGpPWpGaD
Doxorubicin—Asthenia—Docetaxel—skin cancer	2.04e-05	0.000188	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—SUFU—skin cancer	2.03e-05	0.000559	CbGpPWpGaD
Doxorubicin—Pruritus—Docetaxel—skin cancer	2.01e-05	0.000185	CcSEcCtD
Doxorubicin—NOS2—Circadian rythm related genes—IL6—skin cancer	1.98e-05	0.000543	CbGpPWpGaD
Doxorubicin—NOS2—Disease—FOXO4—skin cancer	1.96e-05	0.00054	CbGpPWpGaD
Doxorubicin—Diarrhoea—Docetaxel—skin cancer	1.94e-05	0.000179	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—GLI2—skin cancer	1.93e-05	0.00053	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—ENO2—skin cancer	1.92e-05	0.000528	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.91e-05	0.000525	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—ERCC2—skin cancer	1.91e-05	0.000525	CbGpPWpGaD
Doxorubicin—NOS3—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.91e-05	0.000524	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	1.89e-05	0.000519	CbGpPWpGaD
Doxorubicin—Dizziness—Docetaxel—skin cancer	1.88e-05	0.000173	CcSEcCtD
Doxorubicin—NOS3—Disease—ENO2—skin cancer	1.87e-05	0.000514	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SHH—skin cancer	1.87e-05	0.000514	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—CSPG4—skin cancer	1.87e-05	0.000514	CbGpPWpGaD
Doxorubicin—NOS1—Disease—ERCC2—skin cancer	1.86e-05	0.00051	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—ENO2—skin cancer	1.85e-05	0.000509	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MC1R—skin cancer	1.84e-05	0.000505	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—GLI1—skin cancer	1.81e-05	0.000498	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—FOXO4—skin cancer	1.81e-05	0.000496	CbGpPWpGaD
Doxorubicin—Vomiting—Docetaxel—skin cancer	1.8e-05	0.000166	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—CSPG4—skin cancer	1.79e-05	0.000492	CbGpPWpGaD
Doxorubicin—Rash—Docetaxel—skin cancer	1.79e-05	0.000165	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—NRAS—skin cancer	1.79e-05	0.000491	CbGpPWpGaD
Doxorubicin—Dermatitis—Docetaxel—skin cancer	1.79e-05	0.000165	CcSEcCtD
Doxorubicin—Headache—Docetaxel—skin cancer	1.78e-05	0.000164	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CDK4—skin cancer	1.75e-05	0.000481	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TERT—skin cancer	1.75e-05	0.00048	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PLIN2—skin cancer	1.74e-05	0.000479	CbGpPWpGaD
Doxorubicin—NOS1—Disease—TERT—skin cancer	1.74e-05	0.000478	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.73e-05	0.000475	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—ENO2—skin cancer	1.72e-05	0.000474	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SUFU—skin cancer	1.72e-05	0.000472	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—CDKN2A—skin cancer	1.71e-05	0.00047	CbGpPWpGaD
Doxorubicin—Nausea—Docetaxel—skin cancer	1.69e-05	0.000155	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism—PLIN2—skin cancer	1.69e-05	0.000463	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.68e-05	0.000461	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CSPG4—skin cancer	1.68e-05	0.000461	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ENO2—skin cancer	1.57e-05	0.00043	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CDK4—skin cancer	1.56e-05	0.00043	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SHH—skin cancer	1.55e-05	0.000426	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—RASA1—skin cancer	1.54e-05	0.000423	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—KRAS—skin cancer	1.54e-05	0.000423	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—PTGS2—skin cancer	1.54e-05	0.000423	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—PTGS2—skin cancer	1.54e-05	0.000423	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.54e-05	0.000422	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PLIN2—skin cancer	1.53e-05	0.000421	CbGpPWpGaD
Doxorubicin—NOS3—Disease—FOXO4—skin cancer	1.53e-05	0.000419	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TERT—skin cancer	1.52e-05	0.000419	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—TP53—skin cancer	1.48e-05	0.000406	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTCH1—skin cancer	1.47e-05	0.000404	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SMO—skin cancer	1.47e-05	0.000404	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.45e-05	0.000398	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PTGS2—skin cancer	1.45e-05	0.000397	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTGER4—skin cancer	1.43e-05	0.000393	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CSPG4—skin cancer	1.4e-05	0.000386	CbGpPWpGaD
Doxorubicin—NOS2—Disease—ERCC2—skin cancer	1.4e-05	0.000385	CbGpPWpGaD
Doxorubicin—NOS1—Disease—BRAF—skin cancer	1.38e-05	0.000378	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—TP53—skin cancer	1.37e-05	0.000376	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CSPG4—skin cancer	1.36e-05	0.000373	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—IL6—skin cancer	1.35e-05	0.000371	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—NRAS—skin cancer	1.35e-05	0.000371	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.34e-05	0.000367	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TERT—skin cancer	1.31e-05	0.00036	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SHH—skin cancer	1.31e-05	0.00036	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—HRAS—skin cancer	1.31e-05	0.000359	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—RASA1—skin cancer	1.3e-05	0.000358	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—ERCC2—skin cancer	1.29e-05	0.000353	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ENO2—skin cancer	1.27e-05	0.000349	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—FOXO4—skin cancer	1.26e-05	0.000347	CbGpPWpGaD
Doxorubicin—AURKA—Cell Cycle—TP53—skin cancer	1.26e-05	0.000345	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SMO—skin cancer	1.24e-05	0.000341	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTCH1—skin cancer	1.24e-05	0.000341	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CSPG4—skin cancer	1.24e-05	0.00034	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PTGS2—skin cancer	1.23e-05	0.000338	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ENO2—skin cancer	1.22e-05	0.000335	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTGER4—skin cancer	1.21e-05	0.000332	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—BRAF—skin cancer	1.21e-05	0.000331	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TERT—skin cancer	1.21e-05	0.000331	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—CDKN2A—skin cancer	1.2e-05	0.000329	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.19e-05	0.000327	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—KRAS—skin cancer	1.16e-05	0.000319	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PTGS2—skin cancer	1.15e-05	0.000315	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SHH—skin cancer	1.14e-05	0.000313	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ENO2—skin cancer	1.14e-05	0.000313	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PLIN2—skin cancer	1.12e-05	0.000309	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—ERCC2—skin cancer	1.12e-05	0.000307	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PTGS2—skin cancer	1.11e-05	0.000306	CbGpPWpGaD
Doxorubicin—NOS3—Disease—ERCC2—skin cancer	1.09e-05	0.000299	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—ERCC2—skin cancer	1.08e-05	0.000296	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FOXO4—skin cancer	1.07e-05	0.000293	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—NRAS—skin cancer	1.05e-05	0.000288	CbGpPWpGaD
Doxorubicin—NOS2—Disease—BRAF—skin cancer	1.04e-05	0.000285	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—TP53—skin cancer	1.03e-05	0.000283	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TERT—skin cancer	1.02e-05	0.00028	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—ERCC2—skin cancer	1e-05	0.000275	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.94e-06	0.000273	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—HRAS—skin cancer	9.87e-06	0.000271	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—BRAF—skin cancer	9.55e-06	0.000262	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ENO2—skin cancer	9.55e-06	0.000262	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.53e-06	0.000262	CbGpPWpGaD
Doxorubicin—YWHAG—Cell Cycle—TP53—skin cancer	9.52e-06	0.000261	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FOXO4—skin cancer	9.3e-06	0.000255	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ENO2—skin cancer	9.24e-06	0.000254	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ERCC2—skin cancer	9.1e-06	0.00025	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CSPG4—skin cancer	9.06e-06	0.000249	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—KRAS—skin cancer	9.01e-06	0.000248	CbGpPWpGaD
Doxorubicin—NOS1—Disease—NRAS—skin cancer	8.66e-06	0.000238	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	8.51e-06	0.000234	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TERT—skin cancer	8.44e-06	0.000232	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ENO2—skin cancer	8.4e-06	0.000231	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTGS2—skin cancer	8.39e-06	0.000231	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PLIN2—skin cancer	8.29e-06	0.000228	CbGpPWpGaD
Doxorubicin—NOS3—Disease—BRAF—skin cancer	8.07e-06	0.000222	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—skin cancer	8.01e-06	0.00022	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLIN2—skin cancer	7.81e-06	0.000215	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—skin cancer	7.71e-06	0.000212	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—HRAS—skin cancer	7.66e-06	0.00021	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NRAS—skin cancer	7.58e-06	0.000208	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.47e-06	0.000205	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KRAS—skin cancer	7.45e-06	0.000205	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ERCC2—skin cancer	7.38e-06	0.000203	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.22e-06	0.000198	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TERT—skin cancer	7.13e-06	0.000196	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ERCC2—skin cancer	7.08e-06	0.000194	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—skin cancer	6.7e-06	0.000184	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—BRAF—skin cancer	6.69e-06	0.000184	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CSPG4—skin cancer	6.68e-06	0.000184	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—skin cancer	6.66e-06	0.000183	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERCC2—skin cancer	6.62e-06	0.000182	CbGpPWpGaD
Doxorubicin—NOS2—Disease—NRAS—skin cancer	6.53e-06	0.000179	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KRAS—skin cancer	6.53e-06	0.000179	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—skin cancer	6.52e-06	0.000179	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—skin cancer	6.46e-06	0.000177	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—skin cancer	6.33e-06	0.000174	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CSPG4—skin cancer	6.3e-06	0.000173	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TERT—skin cancer	6.21e-06	0.000171	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ENO2—skin cancer	6.16e-06	0.000169	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—skin cancer	6.06e-06	0.000167	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—skin cancer	6.01e-06	0.000165	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NRAS—skin cancer	6e-06	0.000165	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—skin cancer	5.8e-06	0.000159	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.7e-06	0.000157	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—BRAF—skin cancer	5.65e-06	0.000155	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—skin cancer	5.62e-06	0.000154	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—skin cancer	5.55e-06	0.000152	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ERCC2—skin cancer	5.55e-06	0.000152	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—skin cancer	5.46e-06	0.00015	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ERCC2—skin cancer	5.36e-06	0.000147	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—skin cancer	5.31e-06	0.000146	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—skin cancer	5.17e-06	0.000142	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLIN2—skin cancer	5.11e-06	0.00014	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—skin cancer	5.07e-06	0.000139	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.06e-06	0.000139	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—BRAF—skin cancer	4.92e-06	0.000135	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ERCC2—skin cancer	4.88e-06	0.000134	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—skin cancer	4.78e-06	0.000131	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—skin cancer	4.57e-06	0.000126	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ENO2—skin cancer	4.54e-06	0.000125	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—skin cancer	4.43e-06	0.000122	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—skin cancer	4.39e-06	0.000121	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—skin cancer	4.36e-06	0.00012	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ENO2—skin cancer	4.28e-06	0.000118	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—skin cancer	4.24e-06	0.000117	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—skin cancer	4.2e-06	0.000115	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—skin cancer	4.2e-06	0.000115	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CSPG4—skin cancer	4.12e-06	0.000113	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—skin cancer	3.97e-06	0.000109	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—skin cancer	3.71e-06	0.000102	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—skin cancer	3.62e-06	9.94e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ERCC2—skin cancer	3.58e-06	9.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—skin cancer	3.55e-06	9.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—skin cancer	3.55e-06	9.75e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—skin cancer	3.33e-06	9.14e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—skin cancer	3.22e-06	8.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—skin cancer	3.21e-06	8.83e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—skin cancer	3.09e-06	8.49e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—skin cancer	3.07e-06	8.45e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—skin cancer	3.06e-06	8.4e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—skin cancer	2.94e-06	8.08e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—skin cancer	2.93e-06	8.04e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ENO2—skin cancer	2.8e-06	7.69e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—skin cancer	2.72e-06	7.46e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—skin cancer	2.66e-06	7.31e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ERCC2—skin cancer	2.64e-06	7.25e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—skin cancer	2.6e-06	7.14e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ERCC2—skin cancer	2.49e-06	6.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—skin cancer	2.49e-06	6.83e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—skin cancer	2.26e-06	6.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—skin cancer	2.16e-06	5.94e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—skin cancer	2.15e-06	5.89e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ERCC2—skin cancer	1.63e-06	4.47e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—skin cancer	1.58e-06	4.35e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—skin cancer	1.49e-06	4.1e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—skin cancer	9.75e-07	2.68e-05	CbGpPWpGaD
